Literature DB >> 10453731

Evaluation of the Best disease gene in patients with age-related macular degeneration and other maculopathies.

R Allikmets1, J M Seddon, P S Bernstein, A Hutchinson, A Atkinson, S Sharma, B Gerrard, W Li, M L Metzker, C Wadelius, C T Caskey, M Dean, K Petrukhin.   

Abstract

Vitelliform macular dystrophy (VMD2, Best disease, MIM153700) is an early onset, autosomal, dominant macular degeneration characterized by the deposition of lipofuscin-like material within and below the retinal pigment epithelium (RPE); it is associated with degeneration of the RPE and overlying photoreceptors. Recently, we cloned the gene bestrophin, which is responsible for the disease, and identified a number of causative mutations in families with VMD2. Here, we report that the analysis of bestrophin in a collection of 259 age-related macular degeneration (AMD) patients provides evidence that mutations in the Best disease gene do not play a significant role in the predisposition of individuals to AMD. However, our results suggest that, in addition to Best disease, mutations within the bestrophin gene could be responsible for other forms of maculopathy with phenotypic characteristics similar to Best disease and for other diseases not included in the VMD category.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10453731     DOI: 10.1007/s004390050986

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  48 in total

1.  Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium.

Authors:  A D Marmorstein; L Y Marmorstein; M Rayborn; X Wang; J G Hollyfield; K Petrukhin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

2.  SOX9, through interaction with microphthalmia-associated transcription factor (MITF) and OTX2, regulates BEST1 expression in the retinal pigment epithelium.

Authors:  Tomohiro Masuda; Noriko Esumi
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

Review 3.  Genetic factors of age-related macular degeneration.

Authors:  Jingsheng Tuo; Christine M Bojanowski; Chi-Chao Chan
Journal:  Prog Retin Eye Res       Date:  2004-03       Impact factor: 21.198

Review 4.  [Morbus Best].

Authors:  O Strauss
Journal:  Ophthalmologe       Date:  2005-02       Impact factor: 1.059

Review 5.  Progress in defining the molecular biology of age related macular degeneration.

Authors:  Andrew Lotery; Dorothy Trump
Journal:  Hum Genet       Date:  2007-07-21       Impact factor: 4.132

Review 6.  Bestrophin 1 and retinal disease.

Authors:  Adiv A Johnson; Karina E Guziewicz; C Justin Lee; Ravi C Kalathur; Jose S Pulido; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Prog Retin Eye Res       Date:  2017-01-30       Impact factor: 21.198

Review 7.  The molecular genetic basis of age-related macular degeneration: an overview.

Authors:  Saritha Katta; Inderjeet Kaur; Subhabrata Chakrabarti
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

Review 8.  Genetics of age-related macular degeneration: current concepts, future directions.

Authors:  Margaret M Deangelis; Alexandra C Silveira; Elizabeth A Carr; Ivana K Kim
Journal:  Semin Ophthalmol       Date:  2011-05       Impact factor: 1.975

9.  Suppression of Ca2+ signaling in a mouse model of Best disease.

Authors:  Youwen Zhang; J Brett Stanton; Jiang Wu; Kuai Yu; H Criss Hartzell; Neal S Peachey; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Hum Mol Genet       Date:  2010-01-06       Impact factor: 6.150

10.  Functional and clinical data of Best vitelliform macular dystrophy patients with mutations in the BEST1 gene.

Authors:  Giuseppe Querques; Jennyfer Zerbib; Rossana Santacroce; Maurizio Margaglione; Nathalie Delphin; Jean-Michel Rozet; Josseline Kaplan; Domenico Martinelli; Nicola Delle Noci; Gisèle Soubrane; Eric H Souied
Journal:  Mol Vis       Date:  2009-12-31       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.